Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lineage Cell Therapeutics Inc (NY: LCTX )

1.120 +0.010 (+0.90%)
Streaming Delayed Price Updated: 11:34 AM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 59,548
Open 1.110
Bid (Size) 1.120 (153)
Ask (Size) 1.130 (17)
Prev. Close 1.110
Today's Range 1.110 - 1.140
52wk Range 0.8414 - 1.569
Shares Outstanding 174,986,671
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development
From Lineage Cell Therapeutics, Inc.
Via Business Wire
LCTX Stock Earnings: Lineage Cell Therapeutics Beats EPS, Beats Revenue for Q4 2023
LCTX stock results show that Lineage Cell Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace

Performance

YTD
+2.75%
+2.75%
1 Month
-14.50%
-14.50%
3 Month
+2.75%
+2.75%
6 Month
-2.61%
-2.61%
1 Year
-17.04%
-17.04%

More News

Read More
Lineage Cell Therapeutics: Q4 Earnings Insights
Via Benzinga
A Preview Of Lineage Cell Therapeutics's Earnings
Via Benzinga
Lineage Cell Therapeutics: Q3 Earnings Insights
Via Benzinga
Earnings Preview: Lineage Cell Therapeutics
Via Benzinga
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
From Lineage Cell Therapeutics, Inc.
Via Business Wire
RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Earnings Scheduled For March 7, 2024
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct Offering
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics Announces $14.0 Million Registered Direct Offering
From Lineage Cell Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Lineage Cell Therapeutics, Longeveron And 2 Other Stocks Under $2 Insiders Are Buying
Via Benzinga
Topics Stocks
Exposures US Equities
RG6501 (OpRegen®) Phase 1/2a Results Will Be Featured at 2024 Angiogenesis Exudation and Degeneration Meeting in Presentation by Allen Ho, MD, FACS, FASRS
From Lineage Cell Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Lineage Announces Submission of OPC1 Investigational New Drug Amendment for Treatment of Chronic and Subacute Spinal Cord Injury
From Lineage Cell Therapeutics, Inc.
Via Business Wire
3 Penny Stocks to Buy for the Next Bull Run
Via InvestorPlace
Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on November 9, 2023
From Lineage Cell Therapeutics, Inc.
Via Business Wire
RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at Eyecelerator at 2023 American Academy of Ophthalmology (AAO) Annual Meeting
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.